Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 3
1994 3
1995 2
1996 3
1997 1
1998 4
1999 4
2000 6
2001 7
2002 14
2003 9
2004 12
2005 14
2006 5
2007 7
2008 7
2009 8
2010 14
2011 8
2012 14
2013 9
2014 14
2015 15
2016 13
2017 15
2018 19
2019 16
2020 19
2021 14
2022 15
2023 27
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Results by year

Filters applied: . Clear all
Page 1
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study.
D'Amico F, Gomollón F, Bamias G, Magro F, Targownik L, Leitner C, Heatta-Speicher T, Michelena N, Kolterer S, Lapthorn J, Kauffman L, Dignass A; IBD PODCAST investigators. D'Amico F, et al. Among authors: dignass a. United European Gastroenterol J. 2024 May 11. doi: 10.1002/ueg2.12572. Online ahead of print. United European Gastroenterol J. 2024. PMID: 38733307 Free article.
Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2).
Kucharzik T, Dignass A, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengiesser K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators. Kucharzik T, et al. Among authors: dignass a. Z Gastroenterol. 2024 May;62(5):769-858. doi: 10.1055/a-2271-0994. Epub 2024 May 8. Z Gastroenterol. 2024. PMID: 38718808 Free article. German. No abstract available.
[Update: Addendum to S3-Guidelines Crohn disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease with regard to COVID-19 (version 2.0)].
Schmidt C, Stallmach A, Sturm A, Bachmann O, Helwig U, Koletzko S, Lynen P, Schnoy E, Dignass A, Kucharzik T, Blumenstein I; Collaborators. Schmidt C, et al. Among authors: dignass a. Z Gastroenterol. 2024 Apr;62(4):517-534. doi: 10.1055/a-2255-7184. Epub 2024 Apr 10. Z Gastroenterol. 2024. PMID: 38599579 German. No abstract available.
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus.
Olivera PA, Dignass A, Dubinsky MC, Peretto G, Kotze PG, Dotan I, Kobayashi T, Ghosh S, Magro F, Faria-Neto JR, Siegmund B, Danese S, Peyrin-Biroulet L. Olivera PA, et al. Among authors: dignass a. Dig Liver Dis. 2024 Apr 6:S1590-8658(24)00312-8. doi: 10.1016/j.dld.2024.03.010. Online ahead of print. Dig Liver Dis. 2024. PMID: 38584033 Free article. Review.
Upadacitinib in Crohn's disease.
Dignass A, Esters P, Flauaus C. Dignass A, et al. Expert Opin Pharmacother. 2024 Mar;25(4):359-370. doi: 10.1080/14656566.2024.2333964. Epub 2024 Mar 29. Expert Opin Pharmacother. 2024. PMID: 38512115 Review.
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gibble T, Abreu MT, Lee S, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Arora V, Panaccione R, Dignass A. Sands BE, et al. Among authors: dignass a. Inflamm Bowel Dis. 2024 Mar 9:izae024. doi: 10.1093/ibd/izae024. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38459910
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.
Rahbari NN, Biondo S, Frago R, Feißt M, Kreisler E, Rossion I, Serrano M, Jäger D, Lehmann M, Sommer F, Dignass A, Bolling C, Vogel I, Bork U, Büchler MW, Folprecht G, Kieser M, Lordick F, Weitz J; SYNCHRONOUS and CCRe-IV Trial Groups. Rahbari NN, et al. Among authors: dignass a. J Clin Oncol. 2024 May 1;42(13):1531-1541. doi: 10.1200/JCO.23.01540. Epub 2024 Feb 27. J Clin Oncol. 2024. PMID: 38412408 Clinical Trial.
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus.
Fantini MC, Fiorino G, Colli A, Laharie D, Armuzzi A, Caprioli FA, Gisbert JP, Kirchgesner J, Macaluso FS, Magro F, Ghosh S; PRACTICE-IBD study group. Fantini MC, et al. J Crohns Colitis. 2024 Feb 17:jjae026. doi: 10.1093/ecco-jcc/jjae026. Online ahead of print. J Crohns Colitis. 2024. PMID: 38367197 Free article.
IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management.
Vega P, Huguet JM, Gómez E, Rubio S, Suarez P, Vera MI, Paredes JM, Hernández-Camba A, Plaza R, Mañosa M, Pajares R, Sicilia B, Madero L, Kolterer S, Leitner C, Heatta-Speicher T, Michelena N, Santos de Lamadrid R, Dignass A, Gomollón F. Vega P, et al. Among authors: dignass a. Dig Dis Sci. 2024 Mar;69(3):749-765. doi: 10.1007/s10620-023-08220-9. Epub 2024 Jan 13. Dig Dis Sci. 2024. PMID: 38217680 Free PMC article.
310 results